SCHEMBL20147951

SCHEMBL20147951

CCN1CC(Oc2ccc(C)nn2)C1

nearest known ligand 0.40

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PDE9A O76083 1/20 0.35
RET P07949 5/20 0.34
KDM1A O60341 1/20 0.33
SLC6A4 P31645 2/20 0.33
HRH3 Q9Y5N1 1/20 0.31
IL1B P01584 1/20 0.30
NLRP3 Q96P20 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20148048 0.84 HRH3 (0.48) RETKDM1AHRH3
SCHEMBL20069144 0.77 PDE9A (0.44) PDE9ARETSLC6A4HRH3
SCHEMBL22663347 0.77 RET (0.38) PDE9ARETKDM1AIL1BNLRP3
SCHEMBL13744950 0.74 LOX (0.38) PDE9ARETIL1BNLRP3
SCHEMBL13750552 0.73 LOX (0.41) PDE9ARETIL1BNLRP3
SCHEMBL20412702 0.72 HRH3 (0.43) RETHRH3IL1BNLRP3
SCHEMBL20206022 0.72 SLC6A4 (0.41) RETSLC6A4HRH3
SCHEMBL21733094 0.72 HRH3 (0.41) PDE9ARETHRH3
SCHEMBL22174249 0.71 EGFR (0.45)
SCHEMBL29483133 0.70 HRH1 (0.44) RETSLC6A4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 PDE9A 1154/4885RET 1/4885KDM1A 616/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 PDE9A 1154/4885RET 1/4885KDM1A 616/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 PDE9A 1154/4885RET 1/4885KDM1A 616/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 PDE9A 1154/4885RET 1/4885KDM1A 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.